Innovative Medicines Initiative

There is currently ongoing discussion on the challenges facing the European bio-pharmaceutical industry in relation to drug development. In an attempt to address these challenges, the European Innovative Medicine Initiative (IMI) was launched in 2004. The results are described in the final IMI draft report [17]. 

The Innovative Medicines Initiative Strategic Research Agenda - Creating Biomedical Re D Leadership for Europe to Benefit Patients and Society, Final Draft, 2005, available at eu-ropa.eu.int/comm/research/fp6/ in-dex en.cfm p=l innomecL... 

Hunter AJ. The Innovative Medicines Initiative a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients. Drug Discov Today. 2008,13 371-373. 

Several consortia, primarily driven by pharmaceutical industry members and encouraged by health authorities, have been formed to evaluate and qualify safety biomarkers for use in early clinical drug development trials. In the remainder of this manuscript, we will focus on the safety biomarker qualification efforts of the Critical Path Institute s (C-Path) Predictive Safety Testing Consortium (PSTC), as well as the PSTC collaborations with the Foundation for the National Institutes of Health s Biomarkers Consortium s (FNIH BC) Kidney Safety Project (KSP) and the Innovative Medicines Initiative s (IMI) Safer and Faster Evidence-based Translation Consortium (SAFE-T). Both of these collaborations are driven by the common goal of modernizing safety science through the qualification of clinical safety biomarkers for use in drug development. 

IMI Innovative Medicines Initiative PhRMA Pharmaceutical Research and Manufacturers... 

Testing Consortium and the Innovative Medicine Initiative, which have fueled the pace of research progress in predictive toxicology. These precompetitive collaborations represent ideal forums to share ideas and experience but also to test in an efficient and systematic way new methods for toxicity prediction. These collaborative efforts will undeniably accelerate the development of novel models or biomarkers that will ultimately benefit patients and support animal welfare efforts. Companies and scientists should be encouraged to be actively involved in those forums. 

Part of this work has been performed under the Innovative Medicines Initiative Joint Undertaking under Grant agreement no. 115002 (eTOX) and the EU-ADR project no. 215847. 

IMI (2007). The Innovative Medicines Initiative Assessment of Economical and Societal Effects. http //imi.euroDa.eu/docs/imi-ia-report-032007 en.pdf... 

Goldman M, Seigneuret N, Eichler HG (2015) The Innovative Medicines Initiative an engine for regulatory science. Nat Rev Drug Discov 14 1-2... 

The Innovative Medicines Initiative (IMI) is Europe s largest public-private initiative aiming to accelerate the development of better and safer medicines [27]. IMI supports collaborative research projects with the building of networks comprised of industrial and academic experts in order to boost European pharmaceutical innovation. It is a joint undertaking between the European Union and the European pharmaceutical industry association EFPIA [28]. 

In July 2011, the Innovative Medicines Initiative (IMI) published a call entitled Sustainable Chemistry—Delivering Medicines For The 21st Century . IMI is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations), including the big pharma global corporations as well as small... 

I wish to thank Helen Sneddon and Andrew Wells for their input and helpful discussions during the preparation of this chapter, which is prepared as part of CHEM21. CHEM21 is an Innovative Medicines Initiative Joint Undertaking under grant agreement no 115360, resources of which are composed of financial contribution from the European Union s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in-kind contributions. ... 

The Innovative Medicines Initiative, www.imi.europa.eu. (accessed July 2015). 

The Global Fund and access initiatives that are disease specific include other examples of efforts to raise the financial endovraient needed to generate innovation, product uptake and access to markets for producers, as well as access to medicines for the patients. Their procurement initiatives are designed to support the skills, finance and technological resource endowment required for innovation. In Europe, there has also been renewed policy thinking about how to construct public and private interaction so that appropriate products get to patients (Chataway et al., 2012). Initiatives such as the European Commission s Innovative Medicines Initiatives support basic and applied research (Morgan Jones et al., 2013). 

---